跳至主要内容
临床试验/NCT05666219
NCT05666219撤回4 期

Assessing the Impact of Aminophylline in the Reversal of Complete Heart Block Secondary to Inferior Wall MI in Atropine Resistant Patients: An Open Label Non-randomized Clinical Trial

National Institute of Cardiovascular Diseases, Pakistan0 个研究点目标入组 73 人开始时间: 2022年12月19日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
撤回
入组人数
73
主要终点
Reversal of complete heart block

研究概览

简要总结

In this study, the investigator will evaluate the rate of reversal of complete heart block with aminophylline in atropine resistant patients with inferior wall myocardial infarction (MI)

详细描述

Administration of Aminophylline can result in reversal of complete heart block in a significant number of atropine resistant patients with inferior wall MI. Hence, in this study our primary aim is to evaluate the rate of reversal of complete heart block with aminophylline in atropine resistant patients with inferior wall MI.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients admitted with recent acute inferior wall myocardial infarction (MI)
  • Hemodynamically stable blood pressure
  • Complete heart block with Narrow QRS < 120 ms and ventricular rate >40/min persisting for at least 6 hours, resistant to atropine
  • Temporary pacemaker (TPM) already placed
  • Patient asymptomatic with a mean arterial pressure of greater than 65 mmHg with TPM rate placed at 40/min

排除标准

  • Patients with cardiogenic shock
  • Patients with preexisting permanent pacemaker and Implantable Cardioverter Defibrillator (ICD).
  • Patients with a prior history of AV block
  • Drugs with dromotropic effects (beta blocker, calcium channel blocker, inotropes)
  • Known liver disease (cirrhosis, hepatitis)
  • Hypothyroidism
  • Unable to consent

研究组 & 干预措施

Treatment group

Experimental

Patients receiving Injection Aminophylline

干预措施: Aminophylline Injection (Drug)

结局指标

主要结局

Reversal of complete heart block

时间窗: Within 1 hour of 2nd dose

Conversion to sinus rhythm with 1:1 conduction

次要结局

  • Improved conduction(Within 1 hour of 2nd dose)
  • Major adverse cardiac events (MACE)(Within 12 hours)

研究者

申办方类型
Other
责任方
Sponsor

相似试验